罕见病治疗药物贝捷迈在华获批 国内首个获批用于TGCT治疗一类创新药

中国网财经
Dec 22, 2025

中国网财经12月22日讯 默克今日宣布,国家药品监督管理局(NMPA)已通过优先审评程序批准贝捷迈(盐酸匹米替尼胶囊)用于手术切除可能会导致功能受限或出现较严重并发症的症状性腱鞘巨细胞瘤(TGCT)成年患者。贝捷迈是一款由和誉医药研发的集落刺激因子-1受体(CSF-1R)抑制剂,也是国内首个获批用于TGCT治疗的一类创新药。“随着贝捷迈在全球的首个注册获批,我们正持续践行改善罕见肿瘤患者生活的承诺...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10